Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, Bouwman F, Berkhof J, van Maurik IS, Garibotto V, Moro C, Delrieu J, Payoux P, Saint-Aubert L, Hitzel A, Molinuevo JL, Grau-Rivera O, Gispert JD, Drzezga A, Jessen F, Zeyen P, Nordberg A, Savitcheva I, Jelic V, Walker Z, Edison P, Demonet JF, Gismondi R, Farrar G, Stephens AW, Frisoni GB; Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Consortium. Altomare D, et al. JAMA Neurol. 2023 Jun 1;80(6):548-557. doi: 10.1001/jamaneurol.2023.0997. JAMA Neurol. 2023. PMID: 37155177 Free PMC article. Clinical Trial.
Brain atrophy in Alzheimer's Disease and aging.
Pini L, Pievani M, Bocchetta M, Altomare D, Bosco P, Cavedo E, Galluzzi S, Marizzoni M, Frisoni GB. Pini L, et al. Among authors: altomare d. Ageing Res Rev. 2016 Sep;30:25-48. doi: 10.1016/j.arr.2016.01.002. Epub 2016 Jan 28. Ageing Res Rev. 2016. PMID: 26827786 Review.
Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study.
Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, Pizzocaro C, Lussignoli G, Geroldi C, Zanetti O, Cotelli MS, Turla M, Borroni B, Rozzini L, Mirabile D, Defanti C, Gennuso M, Prelle A, Gentile S, Morandi A, Vollaro S, Volta GD, Bianchetti A, Conti MZ, Cappuccio M, Carbone P, Bellandi D, Abruzzi L, Bettoni L, Villani D, Raimondi MC, Lanari A, Ciccone A, Facchi E, Di Fazio I, Rozzini R, Boffelli S, Manzoni L, Salvi GP, Cavaliere S, Belotti G, Avanzi S, Pasqualetti P, Muscio C, Padovani A, Frisoni GB; Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group. Boccardi M, et al. Among authors: altomare d. JAMA Neurol. 2016 Dec 1;73(12):1417-1424. doi: 10.1001/jamaneurol.2016.3751. JAMA Neurol. 2016. PMID: 27802513
Clinical utility of FDG-PET for the clinical diagnosis in MCI.
Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, Orini S, Barthel H, Agosta F, Drzezga A, Nestor P, Boccardi M, Frisoni GB, Nobili F; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Arbizu J, et al. Among authors: altomare d. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1497-1508. doi: 10.1007/s00259-018-4039-7. Epub 2018 Apr 27. Eur J Nucl Med Mol Imaging. 2018. PMID: 29704037 Review.
Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.
Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Boccardi M, et al. Among authors: altomare d. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1470-1486. doi: 10.1007/s00259-018-4024-1. Epub 2018 Apr 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 29713763 Review.
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, Arbizu J, Bouwman F, Drzezga A, Nestor P, Nobili F, Walker Z, Pagani M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Agosta F, et al. Among authors: altomare d. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717332 Review.
Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.
Nobili F, Festari C, Altomare D, Agosta F, Orini S, Van Laere K, Arbizu J, Bouwman F, Drzezga A, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Nobili F, et al. Among authors: altomare d. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1557-1566. doi: 10.1007/s00259-018-4030-3. Epub 2018 May 2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29721650 Review.
Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, Bouwman F, Orini S, Law I, Agosta F, Arbizu J, Boccardi M, Nobili F, Frisoni GB; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Nestor PJ, et al. Among authors: altomare d. Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1509-1525. doi: 10.1007/s00259-018-4035-y. Epub 2018 May 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29736698 Review.
418 results